Here's some reassurance. This a quote from Part 1 of the BioMedReports covarage of MCLN from December 1:
"As I mentioned in my alert to subscribers, this is a stock that just emerged from sub-penny levels, yet to some it may come as a shock that I continue to stand firmly behind my estimated short term value target of $.40 per share.
"You've lost all credibility," writes another.
Maybe so, but those of us who carefully researched this company, spoke to their management group at length and looked carefully through their books and track record still feel not only bullish about this company, but extremely so."
Notice the wording in red. To me, that's all you should need to be reassured. They've looked through their books and have been able to place a value on the company. To me, the rest of the charts, the discussions, the filings are all noise. Be encouraged, at some point the news will roll out justifying a higher PPS.
